Hazel B. Breitz

2.3k total citations
54 papers, 1.7k citations indexed

About

Hazel B. Breitz is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hazel B. Breitz has authored 54 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Radiology, Nuclear Medicine and Imaging, 20 papers in Oncology and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hazel B. Breitz's work include Radiopharmaceutical Chemistry and Applications (38 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and Medical Imaging Techniques and Applications (9 papers). Hazel B. Breitz is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (38 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and Medical Imaging Techniques and Applications (9 papers). Hazel B. Breitz collaborates with scholars based in United States, Russia and Australia. Hazel B. Breitz's co-authors include Paul L. Weiden, Darrell R. Fisher, Ruby F. Meredith, Michael G. Stabin, Barry W. Wessels, Michael L. Goris, Donald B. Axworthy, John M. Reno, M J Bjorn and Lionel G. Bouchet and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Hazel B. Breitz

52 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hazel B. Breitz United States 24 1.2k 486 325 291 271 54 1.7k
Jean‐François Chatal France 27 1.5k 1.2× 557 1.1× 377 1.2× 267 0.9× 374 1.4× 67 2.2k
J.F. Chatal France 19 1.0k 0.8× 391 0.8× 246 0.8× 132 0.5× 234 0.9× 49 1.4k
D M Goldenberg United States 29 1.4k 1.1× 699 1.4× 285 0.9× 238 0.8× 563 2.1× 85 2.1k
Tom Bäck Sweden 28 1.8k 1.4× 450 0.9× 756 2.3× 122 0.4× 158 0.6× 71 2.0k
Paul G. Abrams United States 21 866 0.7× 519 1.1× 188 0.6× 301 1.0× 434 1.6× 50 1.8k
R.D. Finn United States 12 958 0.8× 268 0.6× 282 0.9× 123 0.4× 231 0.9× 24 1.3k
Christopher C. Badger United States 15 950 0.8× 366 0.8× 226 0.7× 452 1.6× 220 0.8× 26 1.4k
Sture Lindegren Sweden 25 1.7k 1.3× 413 0.8× 708 2.2× 99 0.3× 154 0.6× 79 1.9k
Michael Curcio United States 12 907 0.7× 592 1.2× 305 0.9× 66 0.2× 296 1.1× 16 1.4k
Kwamena E. Baidoo United States 29 1.4k 1.1× 537 1.1× 642 2.0× 52 0.2× 271 1.0× 51 1.8k

Countries citing papers authored by Hazel B. Breitz

Since Specialization
Citations

This map shows the geographic impact of Hazel B. Breitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hazel B. Breitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hazel B. Breitz more than expected).

Fields of papers citing papers by Hazel B. Breitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hazel B. Breitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hazel B. Breitz. The network helps show where Hazel B. Breitz may publish in the future.

Co-authorship network of co-authors of Hazel B. Breitz

This figure shows the co-authorship network connecting the top 25 collaborators of Hazel B. Breitz. A scholar is included among the top collaborators of Hazel B. Breitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hazel B. Breitz. Hazel B. Breitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wessels, Barry W., Mark Konijnenberg, Roger Dale, et al.. (2008). MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response—Implications for Radionuclide Therapy. Journal of Nuclear Medicine. 49(11). 1884–1899. 130 indexed citations
2.
Christoforidou, Anna, Rima M. Saliba, Patricia Williams, et al.. (2007). Results of a Retrospective Single Institution Analysis of Targeted Skeletal Radiotherapy with 166Holmium-DOTMP as Conditioning Regimen for Autologous Stem Cell Transplant for Patients with Multiple Myeloma. Impact on Transplant Outcomes. Biology of Blood and Marrow Transplantation. 13(5). 543–549. 18 indexed citations
3.
4.
5.
Shen, Sui, Ruby F. Meredith, Jun Duan, et al.. (2005). Testicular Uptake and Radiation Dose in Patients Receiving Zevalin ™ and Pretarget ™ CC49Fusion Protein. Cancer Biotherapy and Radiopharmaceuticals. 20(1). 110–118. 3 indexed citations
6.
Forero‐Torres, Andres, Sui Shen, Hazel B. Breitz, et al.. (2005). Pretargeted Radioimmunotherapy (RIT) with a Novel Anti-TAG-72 Fusion Protein. Cancer Biotherapy and Radiopharmaceuticals. 20(4). 379–390. 20 indexed citations
7.
Shen, Sui, Andres Forero, Albert F. LoBuglio, et al.. (2005). Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.. PubMed. 46(4). 642–51. 53 indexed citations
8.
Breitz, Hazel B.. (2004). Clinical Aspects of Radiation Nephropathy. Cancer Biotherapy and Radiopharmaceuticals. 19(3). 359–362. 23 indexed citations
9.
Fisher, Darrell R., Didier A. Rajon, Hazel B. Breitz, et al.. (2004). Dosimetry Model for Radioactivity Localized to Intestinal Mucosa. Cancer Biotherapy and Radiopharmaceuticals. 19(3). 293–307. 5 indexed citations
10.
Forero, Andres, Paul L. Weiden, Julie M. Vose, et al.. (2004). Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood. 104(1). 227–236. 117 indexed citations
11.
Breitz, Hazel B., Richard E. Wendt, Michael G. Stabin, Lionel G. Bouchet, & Barry W. Wessels. (2003). Dosimetry of High Dose Skeletal Targeted Radiotherapy (STR) with 166 Ho-DOTMP. Cancer Biotherapy and Radiopharmaceuticals. 18(2). 225–230. 34 indexed citations
12.
Breitz, Hazel B.. (2002). Dosimetry in a Myeloablative Setting. Cancer Biotherapy and Radiopharmaceuticals. 17(1). 119–128. 9 indexed citations
13.
Weiden, Paul L. & Hazel B. Breitz. (2001). Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL). Critical Reviews in Oncology/Hematology. 40(1). 37–51. 61 indexed citations
14.
Breitz, Hazel B., Paul L. Weiden, Paul L. Beaumier, et al.. (2000). Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.. PubMed. 41(1). 131–40. 124 indexed citations
15.
Weiden, Paul L., Hazel B. Breitz, Oliver W. Press, et al.. (2000). Pretargeted Radioimmunotherapy (PRIT™) for Treatment of Non-Hodgkin's Lymphoma (NHL): Initial Phase I/II Study Results. Cancer Biotherapy and Radiopharmaceuticals. 15(1). 15–29. 110 indexed citations
16.
Breitz, Hazel B., Darrell R. Fisher, Michael L. Goris, et al.. (1999). Radiation Absorbed Dose Estimation for 90 Y-DOTA-biotin with Pretargeted NR-LU-10/Streptavidin. Cancer Biotherapy and Radiopharmaceuticals. 14(5). 381–395. 51 indexed citations
17.
Breitz, Hazel B., et al.. (1997). Clinical Experience With Tc-99m Nofetumomab Merpentan (Verluma) Radioimmunoscintigraphy. Clinical Nuclear Medicine. 22(9). 615–620. 29 indexed citations
18.
Breitz, Hazel B., J. Scott Durham, Darrell R. Fisher, et al.. (1995). Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody.. PubMed. 36(5). 754–61. 15 indexed citations
19.
Breitz, Hazel B., Kathleen M. Sullivan, & Wil B. Nelp. (1993). Imaging lung cancer with radiolabeled antibodies. Seminars in Nuclear Medicine. 23(2). 127–132. 21 indexed citations
20.
Breitz, Hazel B., et al.. (1987). Progressive Pulmonary Calcification Complicating Successful Renal Transplantation. American Review of Respiratory Disease. 136(6). 1480–1482. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean‐François Chatal Breakdown of academic impact, for papers by J.F. Chatal Breakdown of academic impact, for papers by D M Goldenberg Breakdown of academic impact, for papers by Tom Bäck Breakdown of academic impact, for papers by Paul G. Abrams Breakdown of academic impact, for papers by R.D. Finn Breakdown of academic impact, for papers by Christopher C. Badger Breakdown of academic impact, for papers by Sture Lindegren Breakdown of academic impact, for papers by Michael Curcio Breakdown of academic impact, for papers by Kwamena E. Baidoo
Rankless by CCL
2026